Venatorx pharmaceuticals awarded up to $44.2 million to advance novel inhibitors of penicillin binding proteins targeting who critical priority pathogen

This new class of pbp inhibitors has the potential to set the clock back on antibacterial resistance.

DLHC Ratings Summary

DLHC Quant Ranking